Evidence for Immune Response, Axonal Dysfunction and Reduced Endocytosis in the Substantia Nigra in Early Stage Parkinson's Disease

PLoS One. 2015 Jun 18;10(6):e0128651. doi: 10.1371/journal.pone.0128651. eCollection 2015.

Abstract

Subjects with incidental Lewy body disease (iLBD) may represent the premotor stage of Parkinson's disease (PD). To elucidate molecular mechanisms underlying neuronal dysfunction and alpha-synuclein pathology in the premotor phase of PD, we investigated the transcriptome of the substantia nigra (SN) of well-characterized iLBD, PD donors and age-matched controls with Braak alpha-synuclein stage ranging from 0-6. In Braak alpha-synuclein stages 1 and 2, we observed deregulation of pathways linked to axonal degeneration, immune response and endocytosis, including axonal guidance signaling, mTOR signaling, EIF2 signaling and clathrin-mediated endocytosis in the SN. In Braak stages 3 and 4, we observed deregulation of pathways involved in protein translation and cell survival, including mTOR and EIF2 signaling. In Braak stages 5 and 6, we observed deregulation of dopaminergic signaling, axonal guidance signaling and thrombin signaling. Throughout the progression of PD pathology, we observed a deregulation of mTOR, EIF2 and regulation of eIF4 and p70S6K signaling in the SN. Our results indicate that molecular mechanisms related to axonal dysfunction, endocytosis and immune response are an early event in PD pathology, whereas mTOR and EIF2 signaling are impaired throughout disease progression. These pathways may hold the key to altering the disease progression in PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Axons / physiology*
  • Case-Control Studies
  • Disease Progression
  • Endocytosis / physiology*
  • Eukaryotic Initiation Factor-2 / physiology
  • Female
  • Humans
  • In Situ Hybridization
  • Lewy Body Disease / physiopathology
  • Male
  • Oligonucleotide Array Sequence Analysis
  • Parkinson Disease / immunology
  • Parkinson Disease / physiopathology*
  • Signal Transduction / physiology
  • Substantia Nigra / immunology
  • Substantia Nigra / physiopathology*
  • TOR Serine-Threonine Kinases / physiology

Substances

  • Eukaryotic Initiation Factor-2
  • MTOR protein, human
  • TOR Serine-Threonine Kinases

Associated data

  • GEO/GSE49036

Grants and funding

Prinses Beatrix Spierfonds https://www.prinsesbeatrixspierfonds.nl/ projectnumber: WAR07-06 Funding received by WvB. Project number Stichting Parkinson Fonds (www.parkinsonfonds.nl): ZO 02-ANW0702. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.